METHADONE Drug Interactions
Also known as: Methadone Hydrochloride
METHADONE (brand name: Methadone Hydrochloride) is a Opioid Analgesics. 1 INDICATIONS AND USAGE Methadone hydrochloride tablets is indicated for the: Management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. Limitations of Use Because of the risks of…METHADONE has 17 documented drug interactions in our database, including 4 contraindicated, 13 major, 0 moderate, and 0 minor interactions.
4
Contraindicated
13
Major
0
Moderate
0
Minor
The concurrent use of methadone and clonazepam significantly increases the risk of profound sedation, respiratory depression, coma, and death. Patients may exhibit somnolence, decreased level of consciousness, bradycardia, hypotension, and hypoventilation. This combination can also impair psychomotor function, increasing the risk of falls and accidents.
Mechanism
Methadone, an opioid agonist, primarily acts on mu-opioid receptors, leading to central nervous system (CNS) depression, including respiratory depression. Clonazepam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA-A receptors, also causing CNS depression. The co-administration of these two classes of drugs results in additive CNS and respiratory depressant effects.
Clinical Management
Concomitant use of methadone and clonazepam is generally contraindicated due to the severe risks. If co-administration is absolutely unavoidable, the lowest effective doses of both drugs should be used for the shortest possible duration, with close monitoring for signs of respiratory depression and sedation. Consider non-benzodiazepine alternatives for anxiety or insomnia, or opioid-sparing pain management strategies.
The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, pinpoint pupils, and hypotension.
Mechanism
Both methadone, an opioid agonist, and temazepam, a benzodiazepine, are central nervous system (CNS) depressants. Their co-administration leads to additive CNS depression by enhancing GABAergic neurotransmission (benzodiazepines) and activating mu-opioid receptors (methadone), resulting in synergistic effects on respiratory drive and sedation.
Clinical Management
Concomitant use of methadone and temazepam should be avoided due to the high risk. If co-prescription is absolutely necessary and no alternative is available, use the lowest effective doses and shortest possible duration, and closely monitor for respiratory depression and sedation. Educate patients and caregivers on the risks and symptoms, and consider prescribing naloxone.
This interaction significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, and hypotension.
Mechanism
Methadone, an opioid agonist, and triazolam, a benzodiazepine, both cause central nervous system (CNS) depression. When co-administered, their individual depressant effects on the CNS are synergistic, leading to profound suppression of brain activity, particularly in respiratory centers.
Clinical Management
Co-administration of methadone and triazolam is contraindicated. If co-administration is unavoidable, extreme caution is warranted, with reduced dosages of both agents and close monitoring for respiratory depression and sedation. Naloxone should be readily available.
The combination significantly increases the risk of profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, hypoxia, and hypotension. These effects can be rapid in onset and life-threatening.
Mechanism
Methadone, an opioid agonist, primarily acts on mu-opioid receptors, causing central nervous system (CNS) depression, including respiratory depression. Midazolam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter GABA at GABA-A receptors, leading to further CNS depression. The synergistic CNS depressant effects of both drugs significantly increase the risk of severe adverse outcomes.
Clinical Management
Concomitant use is generally contraindicated. If co-administration is unavoidable, use the lowest effective doses and shortest possible duration, and monitor patients closely for respiratory depression and sedation. Consider naloxone for opioid overdose and flumazenil for benzodiazepine overdose, but be aware of potential withdrawal and seizure risks.
Patients may experience increased sedation, dizziness, confusion, and psychomotor impairment. The most serious clinical effects include profound respiratory depression, which can be life-threatening, and hypotension. Impaired motor function and cognitive ability can also increase the risk of falls and accidents.
Mechanism
Methadone is a potent opioid agonist that produces central nervous system (CNS) depression by binding to mu-opioid receptors. Cyclobenzaprine hydrochloride is a centrally acting skeletal muscle relaxant that also causes CNS depression, likely through its anticholinergic effects and action on the brainstem. The co-administration of these two agents results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of methadone and cyclobenzaprine due to the significant risk of additive CNS and respiratory depression. If co-administration is unavoidable, reduce the dosage of one or both drugs, start with the lowest effective dose, and closely monitor patients for signs of respiratory depression, sedation, and hypotension. Educate patients about the risks and advise against operating heavy machinery or driving.
Patients may experience profound sedation, respiratory depression, hypotension, and psychomotor impairment. This can lead to an increased risk of falls, accidental injury, and potentially life-threatening respiratory arrest. The combination can also exacerbate cognitive impairment and decrease the level of consciousness.
Mechanism
Both methadone, an opioid analgesic, and methocarbamol, a centrally acting muscle relaxant, exert depressant effects on the central nervous system (CNS). This interaction is primarily pharmacodynamic, as their combined use leads to an additive or synergistic increase in CNS depression. Methadone acts on opioid receptors, while methocarbamol's exact mechanism is not fully understood but involves general CNS depression.
Clinical Management
Concomitant use should be avoided if possible. If co-administration is unavoidable, initiate both medications at the lowest effective doses and titrate slowly while closely monitoring for signs of CNS and respiratory depression. Educate patients about the risks, advise against operating machinery or driving, and instruct them to seek immediate medical attention for severe drowsiness or breathing difficulties.
Patients may experience profound sedation, respiratory depression, hypotension, psychomotor impairment, and coma. The combination significantly increases the risk of accidental overdose and death. Impaired motor function can also lead to an increased risk of falls and injuries.
Mechanism
Both methadone, an opioid agonist, and carisoprodol, a centrally acting skeletal muscle relaxant, cause central nervous system (CNS) depression. Carisoprodol is metabolized to meprobamate, which is a Schedule IV controlled substance with anxiolytic and sedative properties, further contributing to CNS depression. This additive pharmacological effect leads to an increased risk of severe adverse outcomes.
Clinical Management
Concomitant use should generally be avoided due to the high risk of severe adverse effects. If co-administration is unavoidable, initiate both medications at the lowest effective doses and titrate slowly, monitoring closely for signs of respiratory depression and sedation. Educate patients and caregivers on the risks and symptoms of CNS depression and respiratory compromise.
The primary clinical effects include increased risk of severe respiratory depression, profound sedation, coma, and even death. Patients may experience dizziness, confusion, impaired psychomotor function, and hypotension. These effects are particularly dangerous in opioid-naive individuals or those with pre-existing respiratory compromise.
Mechanism
Methadone is a mu-opioid receptor agonist that causes central nervous system (CNS) depression, including respiratory depression and sedation. Baclofen is a gamma-aminobutyric acid (GABA)-B receptor agonist that also produces CNS depression, muscle relaxation, and sedation. The co-administration of these two agents results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of methadone and baclofen if possible. If co-administration is necessary, initiate both medications at the lowest effective doses and titrate slowly while closely monitoring for signs of respiratory depression and sedation. Educate patients and caregivers about the risks and symptoms of CNS depression and respiratory compromise, and ensure naloxone is available if appropriate.
Patients may experience profound sedation, somnolence, dizziness, and impaired psychomotor function. The most serious clinical effect is an increased risk of respiratory depression, which can be life-threatening. Hypotension and bradycardia may also occur due to additive effects on the cardiovascular system.
Mechanism
Methadone, an opioid agonist, and tizanidine, an alpha-2 adrenergic agonist muscle relaxant, both exert significant central nervous system (CNS) depressant effects. Their co-administration leads to an additive pharmacological effect, increasing the overall level of CNS depression. This synergistic action primarily affects neuronal excitability and neurotransmission in the brain and spinal cord.
Clinical Management
Avoid concomitant use of methadone and tizanidine if possible. If co-administration is unavoidable, initiate both medications at the lowest effective doses and titrate cautiously. Closely monitor patients for signs of respiratory depression, excessive sedation, and changes in mental status, especially during initiation or dose adjustments. Educate patients about the risks and advise against operating heavy machinery or driving.
Patients may experience profound sedation, dizziness, and impaired psychomotor function, increasing the risk of falls and accidents. The most serious clinical effect is an increased risk of respiratory depression, which can be life-threatening. Other effects include mental confusion, hypotension, and syncope.
Mechanism
Both methadone, an opioid analgesic, and metaxalone, a centrally acting muscle relaxant, exert depressant effects on the central nervous system (CNS). The co-administration of these agents leads to an additive pharmacological effect, intensifying CNS depression. This interaction primarily involves their respective actions on neurotransmitter systems that modulate brain activity, resulting in synergistic inhibition.
Clinical Management
Avoid concomitant use if possible. If co-administration is necessary, initiate both drugs at the lowest effective doses and titrate cautiously. Closely monitor patients for signs of respiratory depression, sedation, and altered mental status, especially during initiation or dose changes. Educate patients about the risks and advise against operating heavy machinery or driving.
Patients may experience profound sedation, dizziness, and confusion. There is an increased risk of respiratory depression, which can be life-threatening, and psychomotor impairment, leading to an elevated risk of falls and accidents. Other effects include hypotension and decreased level of consciousness.
Mechanism
Both methadone, an opioid analgesic, and chlorzoxazone, a centrally acting skeletal muscle relaxant, exert depressant effects on the central nervous system (CNS). The co-administration of these agents leads to an additive pharmacological effect, increasing the overall CNS depression. This synergistic action can significantly impair neuronal activity in various brain regions.
Clinical Management
Concomitant use should generally be avoided due to the high risk of severe CNS and respiratory depression. If co-administration is unavoidable, reduce the starting dose of one or both drugs, monitor patients closely for signs of sedation and respiratory depression, and educate them on the risks. Naloxone should be readily available for opioid overdose reversal.
Patients may experience profound sedation, respiratory depression, coma, and even death. Other clinical manifestations include dizziness, confusion, impaired psychomotor function, and hypotension. The risk is heightened in elderly patients or those with pre-existing respiratory compromise.
Mechanism
Methadone is a potent opioid agonist that produces central nervous system (CNS) depression through mu-opioid receptor activation. Orphenadrine citrate, an anticholinergic and antihistaminic agent with muscle relaxant properties, also exerts CNS depressant effects. The co-administration of these agents leads to an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of methadone and orphenadrine due to the significant risk of additive CNS and respiratory depression. If co-administration is unavoidable, reduce the dose of one or both drugs, monitor patients closely for signs of sedation and respiratory depression, and educate them on the risks. Consider alternative non-pharmacological therapies or muscle relaxants with less CNS depressant effects if possible.
The concurrent use of methadone and lorazepam significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased respiratory rate, shallow breathing, hypoxemia, and difficulty arousing. Other effects include dizziness, confusion, psychomotor impairment, and hypotension.
Mechanism
Both methadone, an opioid agonist, and lorazepam, a benzodiazepine, are central nervous system (CNS) depressants. Their co-administration leads to an additive and synergistic depressant effect on the CNS, particularly on the respiratory drive and level of consciousness. This occurs through their respective actions on opioid receptors and GABA-A receptors, leading to enhanced inhibitory neurotransmission.
Clinical Management
Avoid concomitant prescribing of methadone and lorazepam whenever possible. If co-prescription is unavoidable, use the lowest effective doses for the shortest duration possible, and closely monitor patients for signs of respiratory depression and sedation. Educate patients and caregivers about the risks, and provide naloxone if appropriate. Consider non-benzodiazepine alternatives for anxiety or insomnia.
The concurrent use of methadone and diazepam can lead to profound sedation, respiratory depression, coma, and death. Patients may exhibit decreased level of consciousness, hypoventilation, pinpoint pupils, and hypotension. The risk of accidental overdose is significantly increased due to the additive depressant effects on vital functions.
Mechanism
Methadone, an opioid agonist, and diazepam, a benzodiazepine, both act as central nervous system (CNS) depressants. Opioids primarily activate mu-opioid receptors, leading to decreased neuronal excitability, while benzodiazepines enhance the effects of GABA at GABA-A receptors, increasing chloride influx and hyperpolarization. The synergistic CNS depressant effects of these two drug classes significantly potentiate respiratory depression, sedation, and psychomotor impairment.
Clinical Management
Avoid co-prescription of methadone and diazepam whenever possible. If co-administration is unavoidable, reduce the dose of one or both drugs, initiate at the lowest effective dose, and titrate slowly. Monitor patients closely for signs of respiratory depression and sedation, and educate them and their caregivers on the risks, including the availability of naloxone.
Patients may experience severe respiratory depression, profound sedation, coma, and death. Other symptoms include dizziness, lightheadedness, impaired psychomotor function, and hypotension. The risk of overdose is significantly increased.
Mechanism
Both methadone, an opioid analgesic, and alprazolam, a benzodiazepine, are central nervous system (CNS) depressants. Their co-administration leads to an additive depressant effect on the CNS, primarily by enhancing GABAergic neurotransmission (benzodiazepines) and acting on mu-opioid receptors (methadone), resulting in profound respiratory depression and sedation.
Clinical Management
Avoid co-prescription of methadone and alprazolam whenever possible. If concurrent use is unavoidable, prescribe the lowest effective doses for the shortest possible duration, closely monitor for signs of respiratory depression and sedation, and educate patients and caregivers on these risks. Consider naloxone co-prescription and ensure patients understand its use.
Patients may experience profound sedation, respiratory depression (decreased respiratory rate and depth), hypoxia, hypotension, psychomotor impairment, and altered mental status. In severe cases, this can progress to coma, brain injury, and death due to respiratory arrest. The risk is heightened in opioid-naive patients or those with underlying respiratory conditions.
Mechanism
Both methadone, an opioid agonist, and oxazepam, a benzodiazepine, are central nervous system (CNS) depressants. Their co-administration leads to an additive depressant effect on the CNS, particularly affecting the brainstem respiratory centers, leading to reduced respiratory drive and potentially severe hypoventilation. This synergistic effect increases the risk of respiratory depression, profound sedation, and coma.
Clinical Management
Avoid concomitant use of methadone and oxazepam whenever possible. If co-prescription is unavoidable, use the lowest effective doses for the shortest duration possible, and closely monitor patients for signs of respiratory depression and sedation. Educate patients and caregivers about the risks, and ensure naloxone is available if appropriate. Consider alternative non-opioid or non-benzodiazepine therapies.
The concurrent use of methadone and chlordiazepoxide can result in severe and potentially fatal outcomes, including profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, apnea, and hypotension. These effects are particularly dangerous in opioid-tolerant individuals who may still be susceptible to benzodiazepine-induced respiratory depression.
Mechanism
Methadone, an opioid agonist, and chlordiazepoxide, a benzodiazepine, both depress the central nervous system (CNS) by different mechanisms. Methadone acts primarily on mu-opioid receptors, while chlordiazepoxide enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors. Their combined CNS depressant effects are synergistic, leading to profound respiratory depression, sedation, and hypotension.
Clinical Management
Concomitant prescribing of opioids and benzodiazepines should generally be avoided due to the high risk of severe adverse outcomes. If co-prescribing is absolutely necessary, use the lowest effective doses and shortest possible durations, and closely monitor patients for signs of respiratory depression and sedation. Educate patients and caregivers about the risks and symptoms, and consider prescribing naloxone for overdose reversal.
For complete prescribing information:
View full METHADONE monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.